“Cormorant Private Healthcare”

“Cowin China”

“CRF Investment”

“CRMA”

“CRO”

“CSRC”

“CSVC”

DEFINITIONS

Cormorant Private Healthcare Fund I, LP, a limited
partnership incorporated under the laws of Delaware, US
on October 14, 2015 and one of our Pre-IPO Investors

Cowin China Growth Fund I, L.P., an exempted limited
partnership registered under the laws of the Cayman
Islands on November 23, 2012 and one of our Pre-IPO
Investors

CRF Investment Holdings Company Limited,
an
exempted limited liability company incorporated under
the laws of the Cayman Islands on November 14, 2017
and one of our Pre-IPO Investors

CRMA SPV, L.P., an exempted limited partnership
registered under the laws of the Cayman Islands on
October 6, 2015 and one of our Pre-IPO Investors

Contract research organization

China Securities Regulatory Commission

China-Singapore Suzhou Industrial Park Ventures Co.,
Ltd. (中新蘇州工業園區創業投資有限公司), a company
incorporated under the laws of the PRC on November 28,
2001 and one of our Pre-IPO Investors

“Director(s)”

the director(s) of the Company

“EGFR”

“Eli Lilly”

epidermal growth factor receptor

Eli Lilly and Company, a U.S.A. company, organized and
existing under the laws of the State of Indiana on January
17, 1901, having a place of business at Lilly Corporate
Center, Indianapolis, Indiana 46285

“EMA”

European Medicines Agency

“Equity Plans”

“Existing Articles”

the Pre-IPO Share Incentive Plan, the Post-IPO ESOP and
the RS Plan

the twelfth amended and restated memorandum and
articles of association of the Company adopted by special
resolution of the shareholders effective on June 1, 2018

– 22 –

